Atripla

Type: Product
Name: Atripla
First reported Sep 29 2014 - Updated Sep 30 2014 - 1 reports

FDA approves new HIV drug booster cobicistat as its own pill

Facebook Twitter Google + Email PrintOn September 24, 2014, the FDA approved the drug cobicistat as a booster for two HIV medications: atazanavir (Reyataz) and darunavir (Prezista). The drug is used to maintain the blood levels of certain HIV drugs; ... [Published Project Inform - Sep 29 2014]
First reported Sep 28 2014 - Updated Sep 28 2014 - 1 reports

ViiV’s Triumeq to End Gilead’s Monopoly in Anti-HIV, Says GlobalData

The recent approval of ViiV Healthcare’s once-daily, single-tablet anti-HIV regimen, Triumeq, by the US Food and Drug Administration (FDA) and the European Commission (EC) will mean that the market monopoly currently held by Gilead Sciences will soon ... [Published PharmaAsia - Sep 28 2014]
First reported Sep 26 2014 - Updated Sep 26 2014 - 1 reports

Is Gilead Still Cheap?

Summary Rapid rise in the stock price over the past few months have raised some questions about the valuation. Wide economic moat, strong pricing power and low operating expenses will allow the company to continue growth in its fundamentals. Additional ... [Published Seeking Alpha - Sep 26 2014]
First reported Sep 25 2014 - Updated Sep 26 2014 - 1 reports

This Switch Could Make Gilead Sciences, Inc. Stock Billions

What's in a name? For Gilead Sciences ( NASDAQ: GILD     ) , a few billion dollars.Tenofovir alafenamide and tenofovir disoproxil fumarate may sound similar enough (and also a mouthful), but tenofovir alafenamide, commonly referred to as TAF, is worth ... [Published Motley Fool Discussion Boards - Sep 25 2014]
First reported Sep 26 2014 - Updated Sep 26 2014 - 1 reports

My Four-Year Journey With Atripla

This article was cross-posted from " A Girl Like Me ," a program of The Well Project .I want to start this blog by saying this: if you are taking Atripla , remember that everyone's body is different ... I am talking about my own experience and this is ... [Published The Body - Sep 26 2014]
First reported Sep 24 2014 - Updated Sep 24 2014 - 1 reports

Why A $150 Price Target On Gilead Is More Than Possible

By BMD Asset Management and Research :Gilead Sciences (NASDAQ: GILD ) reported strong second-quarter earnings on July 23rd, causing analysts to revise their estimates considerably higher for both this year and next year. While the stock price has risen ... [Published BioPortfolio - Sep 24 2014]
First reported Sep 16 2014 - Updated Sep 16 2014 - 1 reports

Subgroup Analysis of Response to Stribild vs Atripla or Atazanavir: 144 Weeks

ICAAC 2014 54th Interscience Conferenceon Antimicrobial Agents and ChemotherapySeptember 5-9, 2014, Washington, DC ICAAC 2014. September 5-9, 2014. Washington, DC ICAAC: - (09/08/14) Mark MascoliniOverall response to Stribild generally matched responses ... [Published National AIDS Treatment Advocacy Project - Sep 16 2014]
First reported Sep 12 2014 - Updated Sep 12 2014 - 1 reports

Stribild Advantages vs Atripla in Blacks Through Trial Week 144

ICAAC 2014 54th Interscience Conferenceon Antimicrobial Agents and ChemotherapySeptember 5-9, 2014, Washington, DC ICAAC 2014. September 5-9, 2014. Washington, DCFull poster report - ICAAC: - (09/08/14) Mark MascoliniPreviously untreated black study participants ... [Published National AIDS Treatment Advocacy Project - Sep 12 2014]
First reported Sep 11 2014 - Updated Sep 11 2014 - 1 reports

Atripla Is More Than the Sum of Its Three Parts

People with HIV who take Atripla (tenofovir/emtricitabine/efavirenz) take longer to reach virologic failure (if it occurs) and are less likely to develop drug resistance than those who take an equivalent combination therapy as separate pills. These findings ... [Published POZ.com - Sep 11 2014]
Entities: Atripla, Virology, Sustiva
First reported Sep 10 2014 - Updated Sep 11 2014 - 2 reports

Three-in-one combo gets two green lights

LONDON—ViiV Healthcare recently announced a pair of approvals for Triumeq—a combination of dolutegravir, abacavir and lamivudine offering a once-daily regimen for the treatment of HIV infection—the first being approval in the United States on Aug. 22 ... [Published Drug Discovery News - Sep 11 2014]
First reported Sep 09 2014 - Updated Sep 09 2014 - 1 reports

Longer time to virological failure and less drug resistance seen in people taking Atripla than in people taking separate drugs

The study looked at data from eight prospective clinicalcohorts in Europe and North America and four randomised controlled trials(RCTs). To be included in the analysis, participants had to be taking either Atripla , Truvada (tenofovir/emtricitabine) plus ... [Published Aidsmap - Sep 09 2014]
First reported Sep 09 2014 - Updated Sep 09 2014 - 1 reports

Dolutegravir Superior to Efavirenz at 144 Weeks in SINGLE Trial

ICAAC 2014 54th Interscience Conferenceon Antimicrobial Agents and ChemotherapySeptember 5-9, 2014, Washington, DC ICAAC 2014. September 5-9, 2014. Washington, DCMark MascoliniDolutegravir plus abacavir/lamivudine maintained superiority over efavirenz ... [Published National AIDS Treatment Advocacy Project - Sep 09 2014]

Quotes

...Flamel offers investors a second, albeit much more speculative opportunity with its Micropump technology that could rival  Jazz Pharmaceuticals " flagship drug Xyrem in the narcolepsy market. With a forward P/E (based on 2015 estimated EPS) of less than 12, I think the market hasn't fully appreciated the potential upside of the stock."
Original Article: NEXT ARTICLE More From BioPortfolio on "Why A $150 Price Target On Gilead Is More Than Possible"
Witty pointed out that "we have over 40 new molecular entities in late stage development and, across the R&D pipeline, we believe there are a total of 30 drugs with the potential to be first-in-class in areas such as immuno-inflammation, epigenetics and cardiovascular disease. This should lead to a regular flow of new productproduct introduction over the next few years."
...br clear="all" / The researchers proposed that identifying people with efavirenz toxicity "is essential as use of alternate agents leads to improvement in tolerability and toxicity."

More Content

All (61) | News (56) | Reports (0) | Blogs (5) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Is The HIV Divide Now Over? [Published Atlantic Monthly - 11 hours ago]
Is The HIV Divide Now Over? [Published The Daily Dish | By Andrew Sullivan - 11 hours ago]
FDA approves new HIV drug booster cobicistat as... [Published Project Inform - Sep 29 2014]
ViiV’s Triumeq to End Gilead’s Monopoly in Anti... [Published PharmaAsia - Sep 28 2014]
Is Gilead Still Cheap? [Published Seeking Alpha - Sep 26 2014]
My Four-Year Journey With Atripla [Published The Body - Sep 26 2014]
This Switch Could Make Gilead Sciences, Inc. St... [Published Motley Fool Discussion Boards - Sep 25 2014]
The Best Biotech Stock for Your Growth Portfolio [Published Motley Fool Discussion Boards - Sep 25 2014]
Why A $150 Price Target On Gilead Is More Than ... [Published BioPortfolio - Sep 24 2014]
Why A $150 Price Target On Gilead Is More Than ... [Published Seeking Alpha - Sep 24 2014]
The Next Blue Chip Stocks: Gilead Sciences, Inc. [Published Motley Fool Discussion Boards - Sep 24 2014]
Gilead Sciences: A Preview of Important HIV Dru... [Published TheStreet.com - Sep 22 2014]
Gilead Sciences: A Preview of Important HIV Dru... [Published The Street Latest - Sep 22 2014]
Could GlaxoSmithKline Be A Better Investment Th... [Published Seeking Alpha - Sep 17 2014]
Subgroup Analysis of Response to Stribild vs At... [Published National AIDS Treatment Advocacy Project - Sep 16 2014]
Switch From Efavirenz to Rilpivirine Quells CNS... [Published National AIDS Treatment Advocacy Project - Sep 16 2014]
Market Update: Gilead Sciences Inc (NASDAQ:GILD... [Published Jutia Group - Sep 15 2014]
HIV Infection Rates On the Rise in Austin [Published Burnt Orange Report - Sep 12 2014]
Stribild Advantages vs Atripla in Blacks Throug... [Published National AIDS Treatment Advocacy Project - Sep 12 2014]
Atripla Is More Than the Sum of Its Three Parts [Published POZ.com - Sep 11 2014]
PMTCT hailed for reduced HIV transmission [Published Mmegi Online - Sep 11 2014]
Three-in-one combo gets two green lights [Published Drug Discovery News - Sep 11 2014]
ViiV Healthcare receives marketing authorizatio... [Published Individual.com - Sep 10 2014]
Longer time to virological failure and less dru... [Published Aidsmap - Sep 09 2014]
Gilead's monopoly in HIV therapies to be topple... [Published Pharma Letter - Sep 09 2014]
12 Years and Still Going Strong [Published The Body - Sep 09 2014]
Dolutegravir Superior to Efavirenz at 144 Weeks... [Published National AIDS Treatment Advocacy Project - Sep 09 2014]
One Night [Published The Body - Sep 08 2014]
ViiV Healthcare receives FDA approval for HIV-1... [Published Individual.com - Sep 08 2014]
GSK, Pfizer partnership wins EU nod for HIV pil... [Published FiercePharma - Sep 05 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Is The HIV Divide Now Over? [Published The Daily Dish | By Andrew Sullivan - 11 hours ago]
What are your options today as a gay man with a sex life in America? You live in a community where a deadly virus has killed hundreds of thousands and is still resilient in the gay male world as a whole. It has no external or visible symptoms most of ...
HIV Infection Rates On the Rise in Austin [Published Burnt Orange Report - Sep 12 2014]
In the 1980's during the AIDS epidemic, the gay community in Austin lost many members to the disease. Now, infection rates in Austin are again on the rise. Ashley Womble at Austin Monthly looked into this increase, and found that the HIV-positive ...
HIV and Medicare, Even if you Aren't HIV Positive [Published InsureBlog - Aug 14 2014]
Should you have to pay for treatment for a condition you don't have? How about Medicare? Would you expect Medicare to pay for treatment for a Medicare beneficiary if they are not sick? Two years ago, the prescription drug program, known as Part D, ...
Why Gilead Sciences Is a Must-Own Stock [Published Wall St. Cheat Sheet - Jun 30 2014]
Source: Thinkstock Gilead Sciences Inc . ( NASDAQ:GILD ) is one of my top choices for any stocks moving forward through 2014 into 2015. This company is a behemoth of a biopharmaceutical company. It designs, discovers, develops, and commercializes ...
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - May 12 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.